Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.
William Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, discusses updates including preoperative HER2-directed therapy, optimal adjuvant endocrine treatment in premenopausal women, and an approach for managing ER+ metastatic disease.
Christopher Willett, MD, of Duke Cancer Center, discusses short and long courses of treatment, neoadjuvant chemotherapy with or without radiation, and organ preservation without surgery.
Jaffer Ajani, MD, of The University of Texas MD Anderson Cancer Center, discusses the importance of HER2/neu testing and other aspects of treating patients with advanced gastroesophageal adenocarcinoma.
Judith Paice, PhD, RN, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses strategies for safe opioid prescribing: making a comprehensive assessment, stratifying risk, using universal precautions, and educating practitioners on safe storage and disposal.
Alan Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new observations on biomarkers, the best combinations of therapies, and how to sequence them.
